The scientific community is excited about retatrutide, a new dual GIP and GLP-1 receptor that’s showing remarkable promise in {weight loss trials. Early data from the SURPASS-2 study indicate that this drug can lead https://mediajx.com/story28767251/retatrutide-the-new-weight-reduction-hope